Acclarent, Inc. Closes $26 Million Financing

Monday, January 12, 2009 General News
Email Print This Page Comment
Font : A-A+

MENLO PARK, Calif., Jan. 12 Acclarent, Inc., a leadingmedical technology company dedicated to designing, developing andcommercializing devices that address conditions affecting the ear, nose andthroat, announced today the closing of a $26 million dollar financing round.Acclarent intends to use the proceeds to continue commercialization of itsBalloon Sinuplasty(TM) Technology, as well as on-going investment in productdevelopment and clinical studies.

Johnson & Johnson Development Corporation (JJDC) joined existing prominentinvestors New Enterprise Associates, Inc., Delphi Ventures, Versant Ventures,and Meritech Capital Partners in this financing.

"The addition of JJDC together with the support of our existing financialpartners will enable Acclarent to continue executing on our strategy to buildthe preeminent ENT Company," said Bill Facteau, Acclarent President and CEO.

About Johnson & Johnson Development Corporation. Organized in 1973,Johnson & Johnson Development Corporation is the venture capital subsidiary ofJohnson & Johnson. JJDC makes private equity investments in venture fundedhealth care companies. Portfolio companies include those in the fields ofpharmaceuticals, biotechnology, medical devices, diagnostics and consumerproducts. JJDC also leads and manages internal investments in selectedpromising technologies. For more information, go to http://www.jjdevcorp.com.

About Acclarent, Inc.

Acclarent is a medical technology company dedicated to designing,developing and commercializing devices that address conditions affecting theear, nose and throat. The company is currently focused on commercializing itsBalloon Sinuplasty(TM) Devices, which are flexible, minimally-invasive toolsthat aid physicians in treating patients suffering from chronic sinusitis.

SOURCE Acclarent, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook